Evidence map›Paper›PMID 34037841›Full record

ReviewApplied microbiology and biotechnology2021

Biotechnological interventions and genetic diversity assessment in Swertia sp.: a myriad source of valuable secondary metabolites.

Prabhjot Kaur, Devendra Kumar Pandey, R C Gupta, Vijay Kumar, Padmanabh Dwivedi, Rupa Sanyal, Abhijit Dey

RetractedAbstract readReviewRetracted Publication
PubMed Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. From Nature to Nanotechnology: The Bioactivities of Mangiferin Explored.Nanotechnology, science and applications · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Prabhjot KaurDepartment of Biotechnology, Faculty of Technology and Sciences, Lovely Professional University, Phagwara, Punjab, India.
Devendra Kumar PandeyDepartment of Biotechnology, Faculty of Technology and Sciences, Lovely Professional University, Phagwara, Punjab, India. dkpandey1974@gmail.com.
R C GuptaDepartment of Botany, Punjabi University, Patiala, Punjab, 147002, India.
Vijay KumarDepartment of Biotechnology, Faculty of Technology and Sciences, Lovely Professional University, Phagwara, Punjab, India.
Padmanabh DwivediDepartment of Plant Physiology, Institute of Agriculture Sciences, Banaras Hindu University, Varanasi, 221005, India.
Rupa SanyalDepartment of Botany, Bhairab Ganguly College, Kolkata, India.
Abhijit DeyDepartment of Life Sciences, Presidency University, 86/1 College Street, Kolkata, 700073, India. abhijit.dbs@presiuniv.ac.in.ORCID http://orcid.org/0000-0002-5750-0802
Lovely Professional University · INBanaras Hindu University · INPresidency University · INPunjabi University · IN

Funding

Presidency University Faculty Research and Professional Development Fund (FRPDF)
6 · The paper itself

Abstract

The genus Swertia (Family: Gentianaceae) has cosmopolitan distribution which is present in almost all the continents except South America and Australia. Swertia genus has been renowned as one of the potent herbal drugs in the British, American, and Chinese Pharmacopeias as well as well-documented in the Indian traditional medicinal systems, viz. Ayurveda, Siddha, and Unani. Many species of this genus have therapeutic properties and have been used traditionally in the treatment of a number of health ailments viz. hepatitis, diabetes, inflammation, bacillary dysentery, cancer, malaria, fever etc. This genus is industrially important medicinal plant that has been used as a principal component in numerous marketed herbal/ polyherbal formulations. Medicinal usage of Swertia is endorsed to the miscellaneous compounds viz. xanthones, irridoids, seco-irridoids, and triterpenoids. A chain of systematic isolation of bio-active compounds and their diverse range of pharmacological effects during last 15-20 years proved this genus as industrially important plant. Due to the various practices of the Swertia species, annual demand is more than 100 tons per year for this important herb which is continuously increasing 10% annually. The market value rises 10% by the year as there is increased demand in national and international market resulted in adulteration of many Swertia spp. due to paucity of agricultural practices, exomorphological, phytochemical, and molecular characterization. Thus, efficient biotechnology methods are prerequisite for the mass production of authentic species, sustainable production of bio-active compounds and ex situ conservation. A chain of systematic biotechnological interventions in Swertia herb during last 20 years cover the assessment of genetic diversity, in vitro sustainable production of bio-active compounds and mass propagation of elite genotypes via direct and indirect organogenesis. This review attempts to present the comprehensive assessment on biotechnological process made in Swertia over the past few years. KEY POINTS: • Critical and updated assessment on biotechnological aspects of Swertia spp. • In vitro propagation and genetic diversity assessment in Swertia spp. • Biosynthesis and sustainable production of secondary metabolites in Swertia spp.

Indexed as

SwertiaAustraliaBiotechnologyGenetic VariationPlant ExtractsPlant ExtractsElicitorsElite genotypes;Genetic diversity;Phytochemical markers;Plant tissue culture;PrecursorsSwertia;

Identifiers

PMID34037841
OpenAlexW3165076922

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.